Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$11.90 USD
+0.66 (5.87%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.89 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ORIC 11.90 +0.66(5.87%)
Will ORIC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORIC
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
ORIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
Other News for ORIC
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Ufp Technologies (UFPT)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC collaborates with Bayer, J&J on prostate cancer study